Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Oncological Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLC13A5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC13A5 Extracellular Loop (ECL) Recombinant Proteins HEK293 expressed, High purity (>95%), Endotoxin controlled. Sequence Verified. |
View SLC13A5 Products |
| Gene Delivery | SLC13A5 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and functional uptake assays. |
View SLC13A5 Products |
| Benchmark Ab | Anti-SLC13A5 Recombinant Antibody Recombinant positive control for binding and functional blocking. |
View SLC13A5 Products |
| Validator | SLC13A5 siRNA Set For knockdown verification in target-validation assays. |
View SLC13A5 Products |
| Related Target A | SLC13A2 Sodium-dependent dicarboxylate transporter 1 (NaDC1). Crucial for renal counter-screening to prevent off-target toxicity. |
View SLC13A2 Products |
| Related Target B | SLC13A3 Sodium-dependent dicarboxylate transporter 3 (NaDC3). High-affinity transporter utilized for selectivity profiling. |
View SLC13A3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-Pass Membrane Conformation | Lentivirus-mediated stable cell line construction preserves the native 11-transmembrane domain structure. |
| Subfamily Off-Target Screening | Sequence-verified SLC13A2 and SLC13A3 homolog panels available for precise selectivity assays. |
| Lack of Controls | Sequence-defined clinical benchmark antibodies included for assay standardization. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live SLC13A5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLC13A5 therapeutics is intensifying, with major players shifting focus from traditional systemic inhibition to liver-targeted small molecules and monoclonal antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting hepatic citrate uptake to combat non-alcoholic fatty liver disease (NAFLD/NASH), type 2 diabetes, and hepatocellular carcinoma (HCC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Pfizer, Sagesse Bio | Obesity, NAFLD, NASH | Functional Citrate Uptake Assay (Need Lentivirus for Stable Cell Lines) |
| Monoclonal Antibody | Academic Institutions, Biotech | Hepatocellular Carcinoma (HCC) | Epitope Mapping & Binding (Need high-purity ECL Recombinant Proteins) |
| RNA Therapeutics | Alnylam, Ionis | Metabolic Syndrome | Knockdown Efficiency Validation (Need Sequence-Verified siRNA) |